Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 14, 2014

View Archived Issues

Merrimack Pharmaceuticals begins phase II trial of MM-302 in HER2-positive breast cancer

NIPER reports novel PON 1 enzymes

Forma Therapeutics and Paradigm enter into molecular profiling collaboration

Characterization of potential disease-causing mutations in tRNA genes

AstraZeneca reports topline results from pivotal studies of lesinurad for gout

Seattle Genetics begins phase I study of SGN-CD70A

Novogen receives funding to begin studies in muscular dystrophy

Advanced Proteome Therapeutics updates progress of cancer program

Pfizer presents DGAT2 inhibitors with activity in preclinical models of metabolic disease

23andMe and Pfizer collaborate to investigate genetics of inflammatory bowel disease

Flex Pharma reports data for proprietary product for preventing muscle cramps

Novel small-molecule GK-GKRP inhibitors with the ability to lower blood glucose levels in vivo

First-in-class APOBEC3 enzyme inhibitors identified as potential oncolytic candidates

Merck & Co. reports glucokinase activators as diabetes treatment candidates

Novel ACC-beta inhibitors described by Boehringer Ingelheim

New vaccines for Francisella tularensis infection

Researchers at Janssen disclose novel agents for RSV infection

Roche synthesizes new LMP7 inhibitors

FDA approves Belsomra for insomnia

Insys Therapeutics submits NDA for new oral formulation of dronabinol

RedHill Biopharma gains option for RP-101 from RESprotect

Lithera changes name to Neothetics

Phase II trial to test safety and efficacy of fexinidazole in Chagas disease

Sirona subsidiary receives funding for anti-aging project

Rigel's R-348 misses endpoints in keratoconjunctivitis sicca trial

Medicure reports data from phase II trial of Tardoxal in tardive dyskinesia

Allergan acquires lidocaine for interstitial cystitis/bladder pain syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 11, 2025.
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...